期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Lovastatin对肝癌HepG2细胞作用后基因差异表达的初步研究 被引量：3

Effects of lovastatin on differentially expressed genes in HepG2 cells
下载PDF
导出
摘要 目的:用cDNA芯片观察lovastatin作用前后HepG2细胞的差异表达基因。方法:20μmol/L的lovas-tatin作用于HepG2细胞18h,各提取实验组与对照组细胞总RNA,用cDNA直接标记法制备探针,进行杂交,杂交信号经扫描后,用软件分析基因表达情况。应用RT-PCR验证部分差异表达基因。结果:Lovastatin作用后表达上调的基因有30个,表达下调的基因有11个,涉及信号转导、肿瘤免疫、细胞周期等方面,RT-PCR结果符合基因芯片结果。结论:用基因芯片筛选出的lovastatin作用后的肝癌细胞差异表达基因为深入研究他汀类药物的抗肿瘤机制提供重要的理论依据。 AIM： To analyze the lovastatin - induced differential gene expression in HepG2 cells using a eDNA mieroarray assay. METIHODS： Total RNA was extracted from the lovastatin- treated HepG2 cells and control group, eDNA was synthesized from RNA with Cy3/Cy5 - labelled dCTP. Then the-hybridization was conducted. The result was analyzed using Imagene and Genespring software. RT- PCR was carried to confirm the hybridization results. RESULTS： 30 genes were up- regulated while 11 genes were down- regulated in lovastatin- treated HepG2 cells, involved in some major functional areas including signal transduction, cell cycle regulation, tumor immunity, and so on. CONCLUSION： The analysis of differentially expressed genes in lovastatin- treated HepG2 cells is helpful to explore the mechanism of the anti - tumor activity of statins.
作者 吴宝安 梁力建 李绍强 李晓军 彭宝岗
机构地区 中山大学附属第一医院肝胆外科
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2006年第4期781-785,共5页 Chinese Journal of Pathophysiology
关键词 HEPG2细胞 洛伐他汀 基因表达 HepG2 cells Lovastatin Gene expression
分类号 R363 [医药卫生—病理学]
  • 相关文献

参考文献13

  • 1胡允兆,董吁钢,翟玉锋,卢剑华,吴焱贤,周艺,何宗云.辛伐他汀对同型半胱氨酸诱导的HUVEC的毒性和炎症反应的影响及分子机制[J].中国病理生理杂志,2005,21(8):1594-1598. 被引量：7
  • 2韩英,谢良地,许昌声,王华军.氟伐他汀对大鼠血管平滑肌细胞迁移的影响及其机制[J].中国病理生理杂志,2005,21(11):2133-2136. 被引量：18
  • 3Mantha A J,McFee KE,Niknejad N,et al.Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells[J].J Cancer Res Clin Oncol,2003,129(11):631-641.
  • 4Wang CY,Zhong WB,Chang TC,et al.Lovastatin,a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,inducesapoptosis and differentiation in human anaplastic thyroid carcinoma cells[J].J Clin Endocrinol Metab,2003,88(7):3021-3026
  • 5Kawata S,Yamasaki E,Nagase T,et al.Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma.A randomized controlled trial[J].Br J Cancer,2001,84(7):886-891.
  • 6Jakobisiak M,Bruno S,Skierski JS,et al.Cell cycle-specific effects of lovastatin[J].Proc Natl Acad Sci USA,1991,88(9):3828-3632.
  • 7Pardali K,Kowanetz M,Heldin CH,et al.Smad pathwayspecific transcriptional regulation of the cell cycle inhibitor p21(WAF1/Cip1)[J].J Cell Physiol,2005,204(1):260-272.
  • 8Prigent C,Giet R.Aurora A and mitotic commitment[J].Cell,2003,114(5):531-532.
  • 9Kamada K,Yamada Y,Hirao T,et al.Amplification/overexpression of Aurora-A in human gastric carcinoma:potential role in differentiated type gastric carcinogenesis[ J ].Oncol Rep,2004,12(3):593-599.
  • 10Zukerbraum BS,Shapiro RA,Billiar TR,et al.RhoA influences the nuclear location of extracellular signal-regulated kinases to modulate p21Waf/ Cipl expression[ J ].Circulation,2003,108(7):876-881.

二级参考文献27

  • 1郭传勇.内皮素和内皮素受体研究的某些进展[J].生命科学,1993,5(4):13-15. 被引量：5
  • 2Ptashne M, Gann A. Signal transduction. Imposing specificity on kinases[J]. Science, 2003, 299(6212): 1025- 1027.
  • 3Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF - induced activation of nuclear transcription factors NF - kappa B, activator protein - 1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation[J]. J Immunol, 2000, 164(10): 6509-6519.
  • 4Funakoshi- Tago M, Sonoda Y, Tanaka S, et al. Tumor necrosis factor- induced nuclear factor kappaB activation is impaired in focal adhesion kinase- deficient fibroblasts[J]. J Biol Chem, 2003, 278(38): 29359-29365.
  • 5Clark R, Daly L, Robinson K, et al. Hyperhomocysteinemia:an independent risk factor for vascular disease [ J ]. N Engl J Med, 1991, 324(17): 1149- 1155.
  • 6Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis[J]. JACC, 1996, 27(3): 517-527.
  • 7Ross R. The pathogenesis of atherosclerosis: a perspective for 1990s[J]. Nature, 1993, 362(6423): 801 - 809.
  • 8Blundell G, Jones BG, Rose FA, et al. Homocysteine mediated endothelial cell toxicity and its amelioration [ J ].Atherosclerosis, 1996, 122(2): 163-172.
  • 9Bickel C, Rupprecht HJ, Blankenberg S. Influence of HMG CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion [ J ]. Int J Cardiol,2002, 82(1): 25-31.
  • 10Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin [ J ]. Lancet,1999, 353(9157): 983 - 984.

共引文献22

同被引文献26

  • 1张弘,韩喜春,王悦书,韩刚,姜伟栋.基质金属蛋白酶抑制剂-3基因转染抗人肝癌细胞系侵袭与转移的研究[J].中华普通外科杂志,2004,19(6):379-380. 被引量：4
  • 2陈乃云,胡申江,董海涛.应用RNA阵列技术检测自发性高血压大鼠肌浆网钙释放通道基因表达变化[J].中华心血管病杂志,2004,32(7):635-639. 被引量：2
  • 3Maatta M, Soini Y, Lialla A, ct al. Differential expression of matrix metalloproteinases (MMP) -2, MMP-9, and membrane typel-MMP in hepatocellar and pancreatic adenocareinoma: implications for tumor progression and clinical prognosis[ J]. Clin Cancer Res,2000,6 (8) : 2 726 -2 734.
  • 4Aril S,Mise M ,Harada T,et al. Overexpression of matrix metalloproteinases gene in hepatocellar carcinoma with invisive potential [ J]. Hepatology, 1996,24 ( 11 ) : 316 - 322.
  • 5Mort JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases [ J ]. Curr Opin Cell Biol,2004,16 (5) :558 - 564.
  • 6Jodele S, Chantrain CF, Blavier L, et al. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent [ J ]. Cancer Res, 2005,65 ( 8 ) : 3 200 -3 208.
  • 7Polette M, Nawrocki Raby B, Gilles C, et al. Tumor invasion and matrix metalloproteinases[ J ]. Crit Hey Oncol Hematol, 2004,49 ( 3 ) : 179 - 186.
  • 8Giannelli R, Bergamihi C, Fransvea E, et al. Human hepatocellar carcinoma (HCC) cells require both alpha 3 betal integrin and metalloproteinases activity for migration and invasion [ J ]. Lab Invest, 2001,81 (5) :613 - 627.
  • 9Kuzuyama T.Mevalonate and nonmevalonate pathways for the biosynthesis of isoprene units[J].Biosci Biotechnol Biochem,2002,66 (8):1619-1627.
  • 10Hague W,Forder P,Simes J,et al.Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease:results from the long-term intervention with pravastatin in ischemic disease (LIPID) study[J].Am Heart J,2003,145(4):643 -651.

引证文献3

二级引证文献2

中国病理生理杂志
2006年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部